| At MDRNA we are focused on realizing the potential of RNAi-based therapeutics through the development of a broad-based, state-of-the-art drug discovery platform built upon industry leading expertise in RNA chemistry and oligonucleotide delivery. We bring optimal value to our partners, shareholders and ultimately to patients through the discovery and development of RNAi-based therapeutics against human diseases including critical unmet medical needs in areas such as cancer, metabolic disorders and inflammation. More >>
|  | |
|
|
| Date | Title | | | 12/15/08 | MDRNA, Inc. Announces Tentative FDA Approval of Generic Calcitonin-Salmon Nasal Spray for Osteoporosis| BOTHELL, WA, Dec 15, 2008 (MARKET WIRE via COMTEX News Network) -- MDRNA, Inc. (NASDAQ: MRNA) announced today that the U.S. Food and
Drug Administration (FDA) has granted tentative approval of MDRNA's
Abbreviated New Drug Application (ANDA) for generic calcitonin-salmon
nasal spray for the treatment of osteoporosis. Full FDA approval
would follow the completion of Apotex's 180-day exclusivity period,
or June 2009.
MDRNA's generic calcitonin-salmon nasal spray, a legacy product
developed ... |
|  | | 12/03/08 | MDRNA Reports UNA-Modified siRNAs Effectively Silence Gene Targets in Animal Models| Proprietary DiLA2 Platform Continues to Demonstrate Safe and Effective In Vivo Delivery in Repeat Dose Studies BOTHELL, WA, Dec 03, 2008 (MARKET WIRE via COMTEX News Network) -- MDRNA, Inc. (NASDAQ: MRNA) announced today positive in vivo efficacy
data on its proprietary Unlocked Nucleic Acid (UNA) siRNAs in animal
models, demonstrating up to 90% knockdown of ApoB. In addition, the
Company continues to report effective and safe delivery of its Lead
Candidate for hypercholesterolemia in an... |
| | | 11/25/08 | MDRNA, Inc. to Present at Piper Jaffray Healthcare Conference| BOTHELL, WA, Nov 25, 2008 (MARKET WIRE via COMTEX News Network) -- MDRNA, Inc. (NASDAQ: MRNA) announced today that J. Michael French,
President and CEO, will present at the Piper Jaffray Healthcare
Conference on Wednesday, December 3, 2008, at 3:00 p.m. Eastern Time
(12:00 p.m. Pacific Time), at the Palace Hotel in New York City.
To listen to an audio webcast during or after the presentation,
please go to: http://www.mdrnainc.com. A replay of the presentation
will be available for 30 days... |
| | | 11/24/08 | MDRNA, Inc. Receives NASDAQ Notification| BOTHELL, WA, Nov 24, 2008 (MARKET WIRE via COMTEX News Network) -- MDRNA, Inc. (NASDAQ: MRNA) announced today that on November 18, 2008
it received a letter from The NASDAQ Stock Market, Inc. notifying the
Company that, based on the Company's stockholders' equity as reported
in the Quarterly Report on Form 10-Q for the period ended September
30, 2008, it does not comply with the $10 million minimum
stockholders' equity requirement for continued listing on The NASDAQ
Global Market set forth... |
| |
|
|
| Primary IR Contact | Matt Haines
Senior Director, Investor Relations and Corporate Communications
MDRNA Inc.
Phone: 212-209-3874
E-mail: ir@mdrnainc.com |
| | | Transfer Agent | American Stock Transfer & Trust Company
59 Maiden Lane
New York, NY 10038
Phone: 877-777-0800
Corporate Website: http://www.amstock.com
|
| | Legal | Pryor Cashman Sherman & Flynn LLP
410 Park Avenue
New York, NY 10022
Phone: (212) 421-4100
Corporate Website: http://www.pryorcashman.com
|
| | | Accountants | KPMG
3100 Two Union Square
801 Second Avenue
Seattle, WA 98104
Phone: 206-292-1500
Corporate Website: http://www.kpmgcampus.com
|
|
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. |
|
